Over halfway through Phase 2 trials. The new restructured board and management are delivering as they said they would.
Considering this is a software plug in to sleep centres with almost zero COGS, the economics of this type of medical technology play is alomst unrivalled.
If FDA approval is given, the company has a clearly defined moat, with a large TAM see exert from above ann(FDA clearance would unlock a significant market opportunity for the Company. It is estimated that 60 million people in the US suffer from poor sleep quality1 and that 75% of people diagnosed with depression suffer from disrupted sleep patterns) and a product with an amazing GP margin.
Seems pretty good value at a MC of only $13m
Ann: Positive Engagement Meeting with US FDA for MEB-001, page-4
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TRI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $10.05M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 218154 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.3¢ | 34962 | 1 |
View Market Depth
| Last trade - 10.09am 22/08/2024 (20 minute delay) ? |
| TRI (ASX) Chart |
Day chart unavailable